Swiss National Bank Has $8.32 Million Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Swiss National Bank increased its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.0% in the third quarter, HoldingsChannel reports. The firm owned 721,046 shares of the company’s stock after purchasing an additional 6,900 shares during the period. Swiss National Bank’s holdings in Roivant Sciences were worth $8,321,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Mutual of America Capital Management LLC boosted its stake in shares of Roivant Sciences by 0.4% during the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock worth $3,457,000 after acquiring an additional 1,142 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Roivant Sciences by 23.2% in the 2nd quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock worth $89,000 after purchasing an additional 1,603 shares during the last quarter. Covestor Ltd boosted its position in Roivant Sciences by 9.1% during the third quarter. Covestor Ltd now owns 19,190 shares of the company’s stock worth $222,000 after purchasing an additional 1,605 shares during the period. US Bancorp DE grew its holdings in Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after purchasing an additional 1,948 shares during the last quarter. Finally, Gladius Capital Management LP bought a new position in shares of Roivant Sciences in the third quarter valued at approximately $35,000. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ROIV shares. Bank of America upped their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.93.

Insider Buying and Selling

In other news, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the sale, the chief operating officer now owns 606,525 shares of the company’s stock, valued at approximately $6,865,863. This trade represents a 14.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Financial Lp Qvt sold 876,000 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total value of $10,354,320.00. Following the sale, the director now owns 22,179,358 shares in the company, valued at approximately $262,160,011.56. This represents a 3.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,677,309 shares of company stock valued at $43,283,184 over the last three months. 7.90% of the stock is owned by corporate insiders.

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $12.46 on Tuesday. The firm’s 50-day moving average is $11.69 and its 200-day moving average is $11.33. The company has a market cap of $9.07 billion, a price-to-earnings ratio of 2.21 and a beta of 1.24. Roivant Sciences Ltd. has a 52-week low of $8.61 and a 52-week high of $13.06.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.